



Release date: 5 December 2018

NEW APPLICATION RATE FOR ECONASE XT IN LAYING HENS AND PIGS FOR FATTENING PUBLISHED

A new EU application rate has been approved for AB Vista's Econase XT xylanase. Following submission of additional data and a thorough review by EFSA, the European Commission has now published an amended version of the annex, reducing the minimum dosage of Econase XT for laying hens and pigs for fattening. This means that users in the EU can now apply Econase XT in feed for laying hens at a level in line with that normally recommended across the world.

As the most heat resistant xylanase, Econase XT has shown efficacy in broilers, laying hens and pigs, giving benefits across a wide range of feed ingredients in terms of feed efficiency, performance and cost savings.

To find out more about AB Vista's ongoing commitment to xylanase research, including the latest findings related to xylanases as tools to train the microbiome, visit abvista.com, or contact +34918591787 or emea@abvista.com. Follow AB Vista on Twitter: [@ABVista](https://twitter.com/ABVista).

ends

Notes to editor:

AB Vista is an animal nutrition technology company offering pioneering products and technical services to the global animal feed industry. Since its establishment in 2004, AB Vista has grown to be a top-three player in feed enzymes and is also one of the largest suppliers of natural betaine to the global animal nutrition industry. The company invests heavily in research and development and has a growing portfolio of products and services spanning the poultry, swine, ruminant and aquaculture sectors.

AB Vista is headquartered in the UK, with regional offices located in the USA, Brazil, Singapore, Spain, India, China, Germany and Finland.

AB Vista is part of AB Agri, the agricultural division of Associated British Foods, one of Europe's largest food & retail companies with a market capitalisation of £22 billion.

For further press information please contact Sonya Hayden on +44 (0)20 8647 4467 or sonya.hayden@garnettkeeler.com.

ABV/492/18